LCA arises from inherited alterations affecting retinal photoreceptor development and visual signal transduction. The condition demonstrates significant genetic heterogeneity. Certified gene-level records for specific causative variants are not present in this data packet for the broad LCA umbrella grouping.

Diagnosis is based on the combination of profound visual impairment presenting within the first year of life and markedly reduced or undetectable responses on electroretinogram (ERG). Documented affected organ systems include the eye, ear, and nervous system.

No FDA-approved treatments are recorded in this data packet for the broad LCA grouping. Multiple orphan drug designations have been granted for investigational agents targeting specific LCA subtypes; designation does not constitute regulatory approval.

Prognosis data is not certified in this packet. The condition is associated with severe visual impairment from early infancy or childhood.

Thirteen active clinical trials are registered for LCA. The HYPERION Phase 3 trial (NCT06891443, Laboratoires Thea) is recruiting to evaluate sepofarsen in LCA type 10, with anticipated completion October 2028. A Phase 1 subretinal gene transfer study of OPGx-RDH12-1001 (NCT07681778, Opus Genetics) is planned for initiation September 2026 with a primary completion date of July 2034. An expanded newborn screening study (NCT03655223, RTI International) is active but no longer recruiting. The research base includes 178 classified publications dominated by basic science and preclinical research; gene therapy and biomarker publications are present in the record.